PCYC Key Stats
- William Blair's 2014 Top Midcap Picks Street Insider Dec 11
- 11 Game-Changing Drugs Approved by the FDA in 2013 Fool Dec 11
- Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog Zacks Dec 11
- Pharmacyclics (PCYC) Gives Ibrutinib Data in B-Cell Malignancies Street Insider Dec 10
- Keep an Eye on Gilead Sciences, Johnson & Johnson, Pharmacyclics, and AbbVie Today Fool Dec 9
- 2 Top Biotechs Presenting Data At Hematology Event Investor's Business Daily Dec 6
- 4 Potential Blockbuster Drugs Awaiting Launch Investor's Business Daily Dec 5
- Pharmacyclics could beat 2014-2015 consensus estimates, says RBC Capital theflyonthewall.com Dec 3
- Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook Zacks Dec 3
- Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews Zacks Dec 3
PCYC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pharmacyclics is up 73.45% over the last year vs S&P 500 Total Return up 27.09%, Johnson & Johnson up 32.11%, and Auxilium Pharmaceuticals up 13.33%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for PCYC
Pro Report PDF for PCYC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PCYC Pro Report PDF
Pro Strategies Featuring PCYC
Did Pharmacyclics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Its clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. The company has three proprietary drug candidates under clinical development and several preclinical lead molecules which includes Bruton's tyrosine kinase inhibitor, Btk inhibitor lead optimization program and histone deacetylase inhibitor. The company was founded on April 19, 1991 and is headquartered in Sunnyvale, California.